SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Veil Cash is a privacy application leveraging zk-SNARKs on Base L2, enabling verified depositors to achieve privacy and anonymity within a pool of trusted users.  Veil Cash is a non-custodial privacy protocol on Base L2. Veil Cash's goal will be enabling verified users to achieve privacy and anonymity from trusted pools.  Veil is a set of smart contracts that will allow users that are deemed as verified users to deposit into the protocol. Users can later withdraw their deposits from another address without creating a link between these two addresses.   Verified users are those who meet certain criteria based on both on-chain and off-chain data.

Veil-project

The Veil community is rallying around the project's focus on digital privacy and decentralization, often citing its multi-algorithm mining and staking capabilities as key differentiators. Investors are actively discussing the potential for a privacy-focused market surge, frequently highlighting the project's long-term utility alongside established privacy coins.

BioCryst Pharmaceuticals, Inc. is a biotechnology company. It engages in the provision of structure-guided drug design with the goal of developing oral small-molecule and protein therapeutics to target difficult-to-treat rare diseases. The company was founded by William M. Spencer III, Charles E. Bugg, and John A. Montgomery in 1986 and is headquartered in Durham, NC.

Biocryst Pharmaceuticals Inc.

Biocryst Pharmaceuticals is trending as heightened speculation around a potential buyout and unconfirmed M&A rumors drive significant after-hours volume and price volatility. Community members are actively debating the legitimacy of these reports, with long-term shareholders analyzing historical valuation metrics and potential takeover scenarios while others speculate on the motivations behind recent unusual trading patterns.

Blue Owl Capital, Inc. operates as an alternative asset management firm. It provides investors access to asset management capital solutions through its Direct Lending and GP Capital Solutions products. The company offers a platform of capital solutions to both middle market companies and large alternative asset managers. The company was founded by Doug Irving Ostrover, Michael Rees and Craig W.Packer in 2009 and is headquartered in New York, NY.

Blue Owl Capital Inc - Ordinary Shares - Class A

Blue Owl Capital is trending due to significant liquidity concerns following the restricted withdrawal access in its private credit funds, which has sparked investor anxiety over potential sector-wide fallout. The community is actively debating whether this represents an isolated incident or a broader 'canary in the coal mine' moment for private credit stability amidst rising default risks.

Roundhill ETF Trust - Roundhill Ether Covered Call Strategy ETF

oundhill Ether Covered Call Strategy ETF

Investors are closely monitoring YETH as the community debates its weekly distribution payouts versus the underlying volatility of Ethereum. While some traders leverage the fund for its income potential during range-bound market phases, others remain cautious due to concerns regarding NAV erosion and management performance.

Grok's first token launched on Base, deployed directly on X with help of Bankr. Proof of deployment here, https://x.com/grok/status/1897949874961650169.  Join the DRB community if this story intrigues you, follow it as it unfolds into this new AI era.  Grok earns swap fees - Grok's trading wallet: 0xb1058c959987e3513600eb5b4fd82aeee2a0e4f9.  Articles, media coverages on $DRB featured here, https://linktr.ee/DRBtaskforce.  Our dev, is grok, one of the front-running candidate to achieve AGI.

DebtReliefBot

DebtReliefBot is trending as investors rally around its narrative as an AI-generated project linked to the Grok wallet, fueling speculation about its potential for growth within the Base ecosystem. The community remains highly bullish, frequently discussing its low follower count as a sign of being early while emphasizing its unique connection to AI-driven token creation.

ARK ETF Trust - ARK Autonomous Technology & Robotics ETF

ARK Autonomous Technology & Robotics ETF

ARKQ is capturing investor attention as community members debate whether emerging robotics and 'embodied AI' infrastructure will take the tech sector's leadership baton this year. The ETF remains a focal point for discussion regarding portfolio rotation into automation themes, with sentiment driven by institutional buying activity and the sector's long-term growth potential.

Eaton Corp. Plc is a power management company, which provides energy-efficient solutions for electrical, hydraulic, and mechanical power. It operates through the following segments: Electrical Americas and Electrical Global; Aerospace, Vehicle, and eMobility. The Electrical Americas and Electrical Global segments engage in sales contracts for electrical components, industrial components, power distribution and assemblies, residential products, single and three phase power quality, wiring devices, circuit protection, utility power distribution, power reliability equipment, and service. The Aerospace segment supplies aerospace fuel, hydraulics, and pneumatic systems for commercial and military use. The Vehicle segment deals with the design, manufacture, marketing, and supply of drivetrain and powertrain systems and critical components that reduce emissions and improve fuel economy, stability, performance and safety of cars, light trucks and commercial vehicles. The eMobility segment designs, manufactures, markets, and supplies electrical and electronic components and systems that improve the power management and performance of both on-road and off-road vehicles. The company was founded in 1911 and is headquartered in Dublin, Ireland.

Eaton Corporation plc

Eaton Corporation is trending as a major beneficiary of the AI-driven data center expansion, with investors betting on its critical role in power infrastructure and cooling systems. The community is actively discussing its long-term growth as a core industrial leader while monitoring recent price action and technical setups following volatility in the sector.

ARK ETF Trust - ARK Innovation ETF

ARK Innovation ETF

Investors are closely watching the ARK Innovation ETF as it experiences sharp volatility, with community members expressing polarized views on Cathie Wood's aggressive buying and selling patterns amid broader market rotation out of high-beta growth stocks. The ongoing discourse highlights concerns over the fund's long-term performance and its heavy exposure to volatile tech and crypto-linked assets, leading to intense debates between those betting on an innovation-led rebound and those skeptical of the fund's strategy.

Monero

Monero (XMR) is trending as the community debates its role as the premier privacy-focused asset, with active discussions focusing on its unique resistance to regulatory oversight compared to transparent chains. Enthusiasts view it as a long-term store of value and a hedge against institutional tracking, while detractors continue to characterize the asset through speculative or cynical lenses.

NEOS ETF Trust - NEOS Nasdaq 100 High Income ETF

NEOS Nasdaq 100 High Income ETF

Investors are flocking to NEOS Nasdaq 100 High Income ETF (QQQI) to capture high monthly yields while maintaining core exposure to the Nasdaq 100. Community discussion centers on the fund's competitive edge over peers due to its tax-efficient return-of-capital structure and active management strategy, with many users dollar-cost averaging into positions as a long-term retirement income play.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Candel Therapeutics Inc. stock ended Wednesday deep in the red but rose 1.3% in extended trading after the company announced encouraging data from a cancer drug trial.The company reported final survival data from a Phase 2a trial of&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/cadl-stock-jumps-on-canaccord-buy-rating/ch5uUlPRwp">CAN-2409</a> in advanced lung cancer patients who did not respond well to immune checkpoint inhibitors (ICI).&nbsp;The median overall survival (mOS) was 24.5 months for those receiving two courses of CAN-2409, significantly higher than the 9.8-11.8 months seen in similar patients receiving standard chemotherapy.The study included 46 fully treated patients, with 37% of those with progressive disease still alive after two years.&nbsp;Patients with non-squamous non-small cell lung cancer (NSCLC) showed the most potent response, with a mOS of 25.4 months in this group. Biomarker analysis indicated a stronger immune response in these patients than in those with squamous NSCLC.The treatment also appeared to induce a systemic immune response, as 69% of patients with multiple tumors saw reductions in untreated lesions.&nbsp;CAN-2409 maintained a favorable safety profile throughout the extended follow-up period, the company added.The news sent message volume about Candel on Stocktwits soaring by over 120%, with sentiment climbing further within the ‘neutral’ territory (53/100) from a day ago.<figure class="image"><img style="aspect-ratio:1318/302;" src="https://news.stocktwits-cdn.com/CADL_sentiment_and_message_volume_as_of_Macrh_26_png_1c49d17460.webp" alt="CADL sentiment and message volume as of Macrh 26.png" width="1318" height="302"><figcaption>CADL sentiment and message volume as of Macrh 26. | source: Stocktwits</figcaption></figure>One optimistic user said CAN-2409 "is worth billions," adding that Candel also had successful phase-3 trials in prostate cancer and a successful phase-2 in pancreatic cancer.<stembedurl>https://stocktwits.com/strategicmind/message/609387743</stembedurl>Another compared Candel to small-cap biotech firms that were acquired by established pharma giants such as Gilead and Pfizer for tens of billions of dollars, saying the company “will join this GOAT rodeo in no time.”<stembedurl>https://stocktwits.com/chrundel/message/609386559</stembedurl>“I could see this becoming [the] standard of care for adenocarcinoma of the lung,” said another user based on the data.<stembedurl>https://stocktwits.com/Uromaster/message/609354605</stembedurl>Last month, Candel shared updated survival data from Phase 2a trials of CAN-2409 in pancreatic cancer.&nbsp;Meanwhile, Phase 1b survival data for CAN-3110 in recurrent high-grade glioma is expected in the fourth quarter of 2025, and the company plans to submit a Biologics License Application (BLA) for CAN-2409 in prostate cancer in Q4 2026.Candel stock is down about 12% this year but has gained more than 390% in the past 12 months.&nbsp;According to Koyfin, three out of four analysts covering Candel rate it ‘buy’ while one recommends a ‘strong buy.’For updates and corrections, email newsroom[at]stocktwits[dot]com.

Illustration showing chimeric antigen receptor (CAR) T cells (blue and green) being used to treat non-small cell lung cancer (NSCLC). | Representative image: Getty Images

Candel’s Final Survival Data From Lung Cancer Drug Trial Lifts Stock After-Hours, Fuels Retail Optimism

The study included 46 fully treated patients, with 37% of those with progressive disease still alive after two years. 

Equity

The study included 46 fully treated patients, with 37% of those with progressive disease still alive after two years. 


Shares of Candel Therapeutics Inc. surged nearly 10% on Wednesday and extended gains in after-hours trading following a bullish call from Wall Street.Canaccord initiated coverage on the stock with a ‘Buy’ rating and a $20 price target, implying a 91% upside from the last close.&nbsp;The research firm expects continued clinical success for Candel’s lead asset, CAN-2409, in prostate, pancreatic, and non-small cell lung cancer.&nbsp;In testing so far, CAN-2409 has shown a significant increase in median overall survival. If this trend continues, it could become a “best-in-class therapy” for borderline resectable pancreatic ductal adenocarcinoma, according to the analyst.&nbsp;On Stocktwits, sentiment turned ‘extremely bullish’ on Wednesday as message volume jumped by 50% and new followers increased by 4%.&nbsp;<figure class="image"><img style="aspect-ratio:1316/316;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/CADL_sentiment_and_message_volume_Feb_19_d3c9416772.png" alt="CADL sentiment and message volume Feb 19.png" width="1316" height="316"><figcaption>CADL sentiment and message volume Feb 19 | source: Stocktwits</figcaption></figure>Traders speculated that upcoming data could drive a major rally, with some predicting that strong results from the pancreatic study could push shares into the $30-$40 range.<stembedurl>https://stocktwits.com/Xanderzzzzzzz/message/604910450</stembedurl><stembedurl>https://stocktwits.com/drizz/message/604899234</stembedurl>Last week, BofA Securities also&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/cadl-stock-surges-on-bofa-buy-call/chPzAKRRtG">initiated</a> coverage on Candel with a ‘Buy’ rating and a $15 price target, citing promising early data for CAN-2409 and CAN-3110 as key drivers of its bullish outlook.&nbsp;The research firm noted that CAN-2409’s early results in prostate cancer suggest a potential breakthrough, while CAN-3110 has shown signs of nearly doubling overall survival in patients with recurrent high-grade glioma.Candel has outlined several key milestones ahead.&nbsp;Updated overall survival data from Phase 2a trials of CAN-2409 in pancreatic and non-small cell lung cancer is expected in the first quarter of 2025.&nbsp;Phase 1b survival data for CAN-3110 in recurrent high-grade glioma is set for the fourth quarter of 2025, while a Biologics License Application (BLA) submission for CAN-2409 in prostate cancer is targeted for the fourth quarter of 2026.<a href="https://stocktwits.com/symbol/CADL">Candel stock</a> is up more than 22% this year. Short interest was 6.2% as of last week, down from 14.1% at the start of the year, per Koyfin data.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Rising stock market chart on a trading board background.

Candel Therapeutics Stock Rallies On Canaccord’s Vote Of Confidence In Lead Cancer Drug: Retail Traders Rejoice

CAN-2409 could become a “best-in-class therapy” for borderline resectable pancreatic ductal adenocarcinoma, according to the analyst. 

Shares of Mullen Automotive Inc. (MULN) plunged nearly 28% on Wednesday, hitting new record lows after quarterly results showed widening losses that further dented retail investor confidence.The struggling EV maker reported first-quarter (Q1) revenue of $2.9 million, stating that it produced more revenue this quarter than in the past two fiscal years combined.&nbsp;However, net losses ballooned by over 46%, with a net loss of $114.9 million attributable to common shareholders after preferred dividends.While adjusted losses per share narrowed to $661.33 from $91,940.42 a year earlier, the company noted that this figure accounted for retroactive reverse stock splits, including a 1:60 split that took <a href="https://stocktwits.com/news-articles/markets/equity/muln-stock-slides-on-reverse-split-plan/ch5icstRHs">effect</a> this week.&nbsp;Most losses were non-cash expenses totaling $91 million, making up 79% of the quarter's total loss.CEO David Michery tried to highlight a positive milestone, saying that $4.4 million worth of invoices were issued and $6 million in vehicle payments were received, marking Mullen's strongest quarter to date.&nbsp;The company's Bollinger segment completed the sale of 20 units, generating $2.8 million in revenue.<figure class="image"><img style="aspect-ratio:1318/324;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/CVNA_sentiment_and_message_volume_Feb_19_d795e38b8c.png" alt="CVNA sentiment and message volume Feb 19.png" width="1318" height="324"><figcaption>CVNA sentiment and message volume Feb 19 | source: Stocktwits</figcaption></figure>On Stocktwits, sentiment turned 'extremely bearish,' with message volume ticking up as traders weighed Mullen's financial strain.One user pointed to Mullen's crippling balance sheet, noting that the company already owed a lot of money to GEM Group from a lost arbitration case."This is an insolvent company," the user concluded.<stembedurl>https://stocktwits.com/KendallP/message/604814133</stembedurl>Another skeptical trader mocked potential buyers.<stembedurl>https://stocktwits.com/FourFingerFred/message/604807224</stembedurl>Mullen in December submitted a modified plan to the U.S. Department of Energy (DOE) seeking $55 million in matching funds to support U.S.-based battery and pack production.&nbsp;Additionally, the company has implemented cost-cutting measures, reducing headcount and personnel costs by $13 million annually.However, <a href="https://stocktwits.com/symbol/MULN">MULN stock</a> has lost over 99% of its value in the past year, reflecting a sharp decline in investor confidence amid legal hurdles, financial distress, and lackluster sales growth.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Bear Market and falling chart - stock photo

Mullen's Stock Plumbs New Depths After Q1 Net Loss Balloons By 46%, Retail Traders Throw In The Towel

Most losses were non-cash expenses totaling $91 million, making up 79% of the quarter's total loss.

Mullen Automotive shares slid on Friday morning after plunging over 26% in the previous session, as&nbsp;investors responded negatively to the EV maker’s 1-for-60 reverse stock split&nbsp;announcement.&nbsp;The move aims to help Mullen regain compliance with Nasdaq’s $1 minimum bid price rule. The split will take effect on Feb. 18.On Stocktwits, Mullen’s sentiment meter shifted to ‘neutral’ from ‘bullish’ amid increased message volume.&nbsp;<figure class="image"><img style="aspect-ratio:1318/324;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/MULN_sentiment_Feb_14_4cf83233f7.png" alt="MULN sentiment Feb 14.png" width="1318" height="324"><figcaption>MULN sentiment and message volume on Feb 14 as of 10:00 am ET | source: Stocktwits</figcaption></figure>Bearish posts pointed to reports of a legal setback: Mullen lost a lawsuit against GEM Group, which it had accused of unregistered securities dealing and market manipulation.&nbsp;<stembedurl>https://stocktwits.com/KendallP/message/604248065</stembedurl>A court&nbsp;<a target="_blank" rel="noopener noreferrer nofollow" href="https://storage.courtlistener.com/recap/gov.uscourts.nysd.615724/gov.uscourts.nysd.615724.148.0.pdf">filing</a> confirmed the ruling against Mullen, ordering the company to pay over $26 million in damages plus interest within 90 days — a sum that bearish retail traders noted far exceeds the EV maker’s current market capitalization and annual revenue.Mullen only recently moved from pre-revenue development to commercial EV sales, reporting $400,000 in revenue for fiscal 2023 and about $1.1 million in fiscal 2024.&nbsp;However, its net loss for the twelve months ended Sept. 30, 2024, widened as non-cash impairment charges climbed to $119.2 million from $84.6 million the prior year.&nbsp;The company&nbsp;<a target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/news-release/2025/01/24/3015112/0/en/Mullen-Reports-Improved-2024-Financial-Results.html">cited</a> ongoing funding challenges and a sharp decline in its market cap as key drivers of the charge.Cash and equivalents dropped to $10.3 million from $155.3 million a year earlier, while total debt stood just below $20 million.Still, some bullish traders speculated that Mullen’s upcoming quarterly earnings report could trigger a rebound, suggesting the reverse split was strategically timed ahead of the release.&nbsp;<stembedurl>https://stocktwits.com/DEDBEARS/message/604286050</stembedurl>The company has also seen some recent positive developments, including last month’s purchase of battery line equipment from Nikola for its Fullerton facility and new orders for its electric cargo vans from universities in Los Angeles and the San Francisco Bay Area.Earlier this year, Mullen reported better-than-expected road testing&nbsp;<a target="_blank" rel="noopener noreferrer nofollow" href="https://electrek.co/2024/02/29/mullen-sees-better-than-expected-road-testing-results-from-energy-dense-solid-state-batteries/">results</a> for its solid-state batteries, showing promising gains in driving range.&nbsp;Founded in 2014, the company initially sought to revive a defunct EV model before pivoting to develop its vehicles.&nbsp;After a 2020 merger, Mullen <a href="https://stocktwits.com/news-articles/markets/equity/muln-stock-dips-after-cost-cut-plans/cJcQXH5REP">acquired</a> a majority stake in Bollinger Motors in 2023 and bought assets from bankrupt Electric Last Mile Solutions.Despite these efforts, investors remain cautious as Mullen navigates legal hurdles and financial strain.&nbsp;The stock has lost over 99% of its value in the past year, with the upcoming earnings report on Feb. 17 seen as a key test for the company’s growth narrative.For updates and corrections, email newsroom[at]stocktwits[dot]com.

In 2022, Mullen spent $148 million acquiring Bollinger Motors and another $240 million on Electric Last Mile Solutions. Photo courtesy: Mullen

Mullen Automotive Stock In Reverse Gear On 1-For-60 Reverse Split Plan: Retail Sentiment Mixed

The stock has lost over 99% of its value in the past year, with the upcoming earnings report on Feb. 17 seen as a key test for the company’s growth narrative.

Shares of Candel Therapeutics Inc.&nbsp;(CADL)&nbsp;surged over 9% on Friday morning, reaching their highest level in nearly a month and setting the stage for their best weekly gain (+20%) since Dec. 20.BofA Securities initiated coverage of Candel with a 'Buy' rating and a $15 price target, according to The Fly, implying an upside of about 92% from the previous close.&nbsp;The brokerage highlighted promising early data for Candel's two lead drug candidates —&nbsp;<a href="https://stocktwits.com/news-articles/markets/5/cadl-stock-soars-after-prostate-cancer-drug-trial-data/cJa3iD5R0a">CAN-2409</a> and CAN-3110 — as key drivers of its bullish outlook.The analyst noted that CAN-2409's early data in prostate cancer suggests the potential for a meaningful breakthrough, given the lack of significant advancements in available treatments.&nbsp;BofA added that CAN-3110 has shown early indications of nearly doubling overall survival in patients with recurrent high-grade glioma.Last month, Candel provided a broad update on what to expect this year and beyond:<ul style="list-style-type:circle;"><li>Q1 2025: Updated overall survival data from Phase 2a clinical trials of CAN-2409 in pancreatic ductal adenocarcinoma and non-small cell lung cancer.</li><li>Q4 2025: Phase 1b overall survival data for CAN-3110 in patients with recurrent high-grade glioma.</li><li>Q4 2026: Biologics License Application (BLA) submission for CAN-2409 in prostate cancer.</li><li>Upcoming scientific conferences: Presentation of Phase 3 data for CAN-2409 in prostate cancer.</li></ul>Candel also disclosed that its cash and cash equivalents stood at approximately $103 million as of&nbsp;Dec. 31, 2024, which the company expects to fund its operations into the first quarter of 2027.<figure class="image"><img style="aspect-ratio:1318/324;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/CADL_sentiment_and_message_volume_Feb_7_0ea124a0a6.png" alt="CADL sentiment and message volume Feb 7.png" width="1318" height="324"><figcaption>CADL sentiment and message volume Feb 7 as of 11 am ET | source: Stocktwits</figcaption></figure>Stocktwits sentiment on Candel flipped to ‘bullish’ (71/100) on Friday from a ‘bearish’ (42/100) reading last week, amid a spike in message volume.&nbsp;Retail traders cheered BofA's bullish rating, with one urging investors to stay long on the stock.<stembedurl>https://stocktwits.com/LongLTC/message/603284668</stembedurl>Adding to the optimism, a retail investor flagged a 13G&nbsp;<a target="_blank" rel="noopener noreferrer nofollow" href="https://www.sec.gov/Archives/edgar/data/315066/000031506625000400/xslSCHEDULE_13G_X01/primary_doc.xml">filing</a> from Fidelity Investments on Friday, revealing that it now owns a 9.3% stake in Candel.<stembedurl>https://stocktwits.com/jzellner/message/603322436</stembedurl>Notably, according to Koyfin data, short interest in Candel stock dropped from 14.1% at the beginning of January to 6.9% by the end of the month.<a href="https://stocktwits.com/symbol/CADL">Candel shares</a> have skyrocketed 560% over the past 12 months — and with bullish sentiment building, some traders believe the rally is far from over.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Photo caption: BofA’s $15 price target implies an upside of about 92% from the previous close. | Image source: Getty Images

Candel Therapeutics Stock Headed For 20% Weekly Gains: Retail Over The Moon With BofA's 'Buy' Call

The analyst noted that CAN-2409's early data in prostate cancer suggests the potential for a meaningful breakthrough, given the lack of significant advancements in available treatments.

ProShares Trust - ProShares Hedge Replication ETF

Opendoor ($OPEN)

Strategy ($MSTR)

American Eagle ($AEO)

Ondas Inc. ($ONDS)

The stock that proved the power of the crowd. Fueled by community energy and social momentum, this winner captivated retail investors regardless of what the "experts" or traditional fundamentals had to say.

HDG
ProShares Hedge Replication ETF

Feed

News

Sentiment

Fundamentals

Info

Poll

Latest HDG News

HDGProShares Hedge Replication ETF